Curanex Pharmaceuticals Inc. CURX 深 滬
等待開盤 03-26 09:30:00 美东时间
0.518
+0.006
+1.07%
華盛通- 最 高0.555
- 今 開0.55
- 成交量 54.93万股
- 最 低 0.49
- 昨 收 0.5125
- 總市值 1468.05万
- 52周最高 9.1796
- 市盈率 靜 --
- 換手率 1.94%
- 52周最低 0.262
- 委 比 50.00%
- 總股本 2834.08万
- 歷史最高 9.1796
- 量 比 1.27
- 振 幅 12.68%
- 歷史最低 0.262
- 每 手 1
- 風險率 2.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Curanex Phyto-N repeat-dose study shows no toxicology findings at maximum feasible dose
Curanex Phyto-N repeat-dose study shows no toxicology findings at maximum feasible dose Curanex reported results from a 28-day repeat-dose, dose-range finding toxicology study of its botanical drug candidate Phyto-N in Sprague-Dawley rats and dogs. Phyto-N was administered orally twice daily, and no
03-19 08:43
Curanex appoints Taku Kambayashi and Selvakumar Subbian to scientific advisory board
Curanex appoints Taku Kambayashi and Selvakumar Subbian to scientific advisory board Curanex appointed Taku Kambayashi and Selvakumar Subbian to its Scientific Advisory Board. Taku Kambayashi is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania’s Perelman School of M
03-12 21:30
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
Curanex Pharmaceuticals Inc. has appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board, bringing expertise in immunology and infectious diseases to support the company's preclinical studies, IND submission, and clinical trials. Dr. Kambayashi, a professor at the University of Pennsylvania, specializes in immune cell signaling pathways and therapeutic targets for inflammatory diseases. Dr. Subbian, a professor a...
03-12 13:30
Curanex Forms World Class Scientific Advisory Board
<p>Curanex Pharmaceuticals Inc. announced the formation of a new Scientific Advisory Board to support its research, development, clinical trials, and commercialization efforts. The board consists of five world-class members with expertise in life sciences. The company highlighted its lead botanical drug candidate, Phyto-N, which is advancing through FDA-required preclinical studies for potential Phase I clinical trials in late 2026. Phyto-N has s...
03-05 13:00
What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours
Curanex Pharmaceuticals shares surged in after-hours trading after the company completed a GMP-compliant batch supporting its planned IND submission for ulcerative colitis.
02-26 15:11
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during W...
02-26 05:07
Curanex Pharmaceuticals Faces Nasdaq Delisting Warning
The latest update is out from Curanex Pharmaceuticals Inc. ( ($CURX) ). On Nove...
2025-11-07 02:57
Curanex Pharmaceuticals Receives Nasdaq Delisting Warning for Low Share Price
Curanex Pharmaceuticals Inc. announced that it has received a notice from the Nasdaq Stock Market indicating that its common stock has closed below the required minimum bid price of $1.00 per share fo...
2025-11-07 02:41
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement
Curanex Pharmaceuticals has partnered with Strategic Investor Relations to enhance its visibility and communication with investors. The company focuses on developing botanical drugs for inflammatory diseases, with its lead candidate, Phyto-N, targeting ulcerative colitis. Curanex aims to advance its pipeline, supported by decades of clinical evidence, and improve shareholder value through effective investor engagement.
2025-10-22 11:00
Curanex Pharmaceuticals Issues Shares Post-IPO
Curanex Pharmaceuticals Inc. ( ($CURX) ) has issued an update. On September 25,...
2025-09-30 04:18
